MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ
6.77
+0.58
+9.37%
After Hours: 6.99 +0.22 +3.25% 19:53 02/07 EST
OPEN
6.64
PREV CLOSE
6.19
HIGH
6.91
LOW
6.42
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
7.99
52 WEEK LOW
2.355
MARKET CAP
396.45M
P/E (TTM)
-6.0821
1D
5D
1M
3M
1Y
5Y
Aldeyra stock rises as dry eye disease drug gets FDA review
Seeking Alpha · 14h ago
BRIEF-Aldeyra Therapeutics Announces FDA Acceptance Of New Drug Application For Reproxalap
Reuters · 14h ago
Aldeyra Therapeutics Says FDA Accepts New Drug Application for Dry Eye Disease Drug Reproxalap
Aldeyra Therapeutics Says FDA Accepts New Drug Application for Dry Eye Disease Drug Reproxalap
MT Newswires · 15h ago
--Street Color: US FDA Accepts Aldeyra Therapeutics' New Drug Application for Dry Eye Disease Drug Candidate
--Street Color: US FDA Accepts Aldeyra Therapeutics' New Drug Application for Dry Eye Disease Drug Candidate
MT Newswires · 15h ago
BRIEF-Aldeyra Therapeutics Says Entered Into Second Amendment To Loan And Security Agreement
Reuters · 12/27/2022 14:32
BRIEF-Aldeyra Therapeutics Submits NDA To U.S. FDA For ADX‑2191
Reuters · 12/21/2022 12:21
Aldeyra Therapeutics Submits New Drug Application for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics Submits New Drug Application for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
MT Newswires · 12/21/2022 07:40
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
Benzinga · 12/13/2022 18:37
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.